Background
Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) is a novel immunotherapy that has achieved success in the treatment of various hematological malignancies.
The concept behind CAR-T therapy is to empower the immune system to attack cancer cells. In short, a patient’s T cells are isolated and genetically engineered to express a chimeric antigen receptor (CAR), which recognises specific tumour-associated antigens, such as CD19, a cell surface protein highly expressed on malignant B cells. Upon recognising the antigen on tumour cells, CAR-T cells initiate a series of immune responses to kill the tumour cells. With an increasing number of CAR-T drugs being approved for marketing (such as Kymriah and Yescarta), CAR-T cell therapy has entered a period of rapid development, demonstrating immense potential.
Comprehensive Catalog of CAR-T Target Proteins
Leveraging their unique SAMS™ protein engineering and expression platform, KACTUS has developed a series of high-quality CAR-T target protein products, covering a wide range of popular targets such as CD19, BCMA, and MSLN. They also offer various modifications including site-specific labelling, fluorescent labelling, and biotinylation, flexibly meeting diverse research and development needs such as CAR-T affinity assays. If you don’t see what you’re looking for in their catalog, you can always request a custom protein.
Product Features
- HEK293 Expression
- His-Avi, hFc, mFc, His, hFc-Avi, etc. protein tags
- Bioactivity verified (ELISA & SPR)
- High Purity
- Human, Mouse, Cynomolgus, Rhesus Macaque, Rat
- Biotinylated Proteins
Product Applications
- CAR-T immunity studies
- Antibody screening (such as scFv, single domain antibody, etc.)
- CAR-T affinity studies
Product Validation Data
KACTUS offers a wide range of fluorescent-labelled target proteins that streamline CAR detection by eliminating the need for secondary antibodies, reducing background staining, and increasing efficiency. Their portfolio includes popular target antigens relevant to current CAR-T research, all with high bioactivity, uniformity, and batch-to-batch consistency.
Leveraging their advanced protein expression platform, KACTUS also provides a comprehensive solution for protein customisation. They offer various modifications such as site-specific labelling, fluorescent labeling (FITC, PE, APC, and others), and biotinylation, to meet various research requirements such as CAR-T affinity testing.
FITC-Compatible Human CD19
FACS data demonstrating that 100 µl of FITC-Compatible Human CD19 (His Tag) (10 µg/ml) can specifically bind to 1×106 Anti-CD19 CAR T cells, resulting in a positive detection rate greater than 96%. FITC-labeled irrelevant protein (100 µl, 10 µg/ml) was used as a negative control.
PE-Labeled Human EGFRVIII
FACS analysis of Anti-EGFRVIII CAR Expression. 293T cells were transfected with anti-EGFRVIII-scFv and His tag. Cells were incubated with 5 µg/ml PE-Labeled Human EGFRVIII (His-Avi Tag) and PE-labelled protein control. Non-transfected 293T cells and PE-labelled protein control were used as negative controls. The PE-labeled Human EGFR VIII specifically binds to Anti-EGFR VIII-CAR T cells, with a positive detection rate of over 99%.
Biotinylated Human MSLN/Mesothelin
FACS analysis of Anti-MSLN-CAR expression. 293T cells were transfected with anti-MSLN-scFv and Fc tag. These cells were stained with 5 µg/ml FITC-Labeled Human MSLN (296-580), Fc Tag, and a FITC-labeled protein control. Non-transfected 293T cells and FITC-labeled protein control were used as negative controls. FITC-labeled SA was used to confirm that Biotinylated Human MSLN (hFc-Avi Tag) can specifically bind to Anti-MSLN-CAR 293T cells, resulting in a positive rate greater than 99%.
Caltag Medsystems is the distributor of KACTUS products in the UK and Ireland. If you have any questions about these products, please contact us.